Switch theme
Sign up to access all valuation multiples
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
2019
78
LTM Revenue $5.2M
Last FY EBITDA -$101M
$297M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Dianthus Therapeutics has a last 12-month revenue (LTM) of $5.2M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Dianthus Therapeutics achieved revenue of $6.2M and an EBITDA of -$101M.
Dianthus Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Dianthus Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.2M | XXX | $6.2M | XXX | XXX | XXX |
| Gross Profit | $5.2M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$101M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1627% | XXX | XXX | XXX |
| EBIT | -$118M | XXX | -$102M | XXX | XXX | XXX |
| EBIT Margin | -2272% | XXX | -1634% | XXX | XXX | XXX |
| Net Profit | -$102M | XXX | -$85.0M | XXX | XXX | XXX |
| Net Margin | -1964% | XXX | -1363% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Dianthus Therapeutics's stock price is $17.
Dianthus Therapeutics has current market cap of $559M, and EV of $297M.
See Dianthus Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $297M | $559M | XXX | XXX | XXX | XXX | $-2.87 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Dianthus Therapeutics has market cap of $559M and EV of $297M.
Dianthus Therapeutics's trades at 47.6x EV/Revenue multiple, and -2.9x EV/EBITDA.
Equity research analysts estimate Dianthus Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dianthus Therapeutics has a P/E ratio of -5.5x.
See valuation multiples for Dianthus Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $559M | XXX | $559M | XXX | XXX | XXX |
| EV (current) | $297M | XXX | $297M | XXX | XXX | XXX |
| EV/Revenue | 56.9x | XXX | 47.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -2.9x | XXX | XXX | XXX |
| EV/EBIT | -2.5x | XXX | -2.9x | XXX | XXX | XXX |
| EV/Gross Profit | 57.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.5x | XXX | -6.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDianthus Therapeutics's last 12 month revenue growth is -30%
Dianthus Therapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.4M for the same period.
Dianthus Therapeutics's rule of 40 is -1722% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Dianthus Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Dianthus Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -30% | XXX | -25% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1627% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1722% | XXX | -1657% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1333% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1734% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dianthus Therapeutics acquired XXX companies to date.
Last acquisition by Dianthus Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Dianthus Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Dianthus Therapeutics founded? | Dianthus Therapeutics was founded in 2019. |
| Where is Dianthus Therapeutics headquartered? | Dianthus Therapeutics is headquartered in United States of America. |
| How many employees does Dianthus Therapeutics have? | As of today, Dianthus Therapeutics has 78 employees. |
| Who is the CEO of Dianthus Therapeutics? | Dianthus Therapeutics's CEO is Mr. Marino Garcia. |
| Is Dianthus Therapeutics publicy listed? | Yes, Dianthus Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Dianthus Therapeutics? | Dianthus Therapeutics trades under DNTH ticker. |
| When did Dianthus Therapeutics go public? | Dianthus Therapeutics went public in 2023. |
| Who are competitors of Dianthus Therapeutics? | Similar companies to Dianthus Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Dianthus Therapeutics? | Dianthus Therapeutics's current market cap is $559M |
| What is the current revenue of Dianthus Therapeutics? | Dianthus Therapeutics's last 12 months revenue is $5.2M. |
| What is the current revenue growth of Dianthus Therapeutics? | Dianthus Therapeutics revenue growth (NTM/LTM) is -30%. |
| What is the current EV/Revenue multiple of Dianthus Therapeutics? | Current revenue multiple of Dianthus Therapeutics is 56.9x. |
| Is Dianthus Therapeutics profitable? | Yes, Dianthus Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
